BioAge Labs (NASDAQ:BIOA) Issues Earnings Results

BioAge Labs (NASDAQ:BIOA) issued its quarterly earnings results on Thursday. The company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.05), FiscalAI reports. BioAge Labs had a negative return on equity of 28.99% and a negative net margin of 912.26%. The business had revenue of $0.30 million during the quarter.

BioAge Labs Stock Down 1.6%

BIOA traded down $0.09 during midday trading on Friday, reaching $5.45. 26,392 shares of the company’s stock were exchanged, compared to its average volume of 719,256. The business has a 50-day simple moving average of $7.08 and a two-hundred day simple moving average of $15.56. The firm has a market capitalization of $250.16 million, a price-to-earnings ratio of -2.29 and a beta of 1.19. BioAge Labs has a one year low of $4.81 and a one year high of $25.95.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. UBS Group began coverage on shares of BioAge Labs in a research report on Sunday, October 11th. They issued a “neutral” rating and a $8.00 price target on the stock. Jefferies Financial Group set a $21.00 price objective on shares of BioAge Labs in a research report on Friday, July 31st. Wall Street Zen cut shares of BioAge Labs from a “sell” rating to a “strong sell” rating in a research note on Saturday, October 10th. Roth Capital reissued a “buy” rating and set a $25.00 target price on shares of BioAge Labs in a research report on Wednesday, September 9th. Finally, Weiss Ratings raised BioAge Labs from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, October 26th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $33.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. acquired a new stake in BioAge Labs in the second quarter worth about $69,831,000. Jupiter Topco LLC acquired a new position in BioAge Labs during the 2nd quarter valued at about $52,597,000. Janus Henderson Group PLC lifted its position in BioAge Labs by 411.8% during the 1st quarter. Janus Henderson Group PLC now owns 2,094,270 shares of the company’s stock valued at $36,597,000 after purchasing an additional 1,685,063 shares during the period. Octagon Capital Advisors LP lifted its position in BioAge Labs by 9.4% during the 1st quarter. Octagon Capital Advisors LP now owns 1,748,000 shares of the company’s stock valued at $30,573,000 after purchasing an additional 150,000 shares during the period. Finally, Walleye Capital LLC bought a new position in shares of BioAge Labs in the 2nd quarter valued at about $8,686,000.

About BioAge Labs

BioAge Labs, Inc is a clinical-stage biotechnology company focused on developing medicines that target the biological mechanisms of aging. The company seeks to address diseases associated with aging by identifying therapeutic targets linked to human longevity and translating those discoveries into drug candidates.

BioAge uses large human data sets, computational biology, and machine-learning tools to study the molecular factors that influence healthy aging and age-related disease. Its research has produced a pipeline of investigational therapies, including azelaprag (BGE-105), an apelin receptor agonist being evaluated for potential applications involving metabolic health, body composition, and physical function.

Founded in 2015, BioAge is headquartered in Richmond, California, and conducts research and clinical development activities through collaborations and studies involving patients and research sites in multiple regions.